Takeda Pharmaceutical (NYSE:TAK) Issues FY 2025 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 3.360-3.360 for the period. The company issued revenue guidance of $31.3 billion-$31.3 billion.

Analyst Ratings Changes

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Trading Up 0.0%

Shares of NYSE TAK opened at $14.32 on Wednesday. The stock’s 50 day moving average price is $14.90 and its two-hundred day moving average price is $14.50. Takeda Pharmaceutical has a 52-week low of $12.80 and a 52-week high of $15.53. The stock has a market capitalization of $45.55 billion, a P/E ratio of 65.07 and a beta of 0.23. The company has a quick ratio of 0.52, a current ratio of 1.01 and a debt-to-equity ratio of 0.57.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). The company had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. On average, analysts anticipate that Takeda Pharmaceutical will post 1.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TAK. Goldman Sachs Group Inc. raised its holdings in shares of Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after acquiring an additional 692,404 shares in the last quarter. Royal Bank of Canada grew its position in shares of Takeda Pharmaceutical by 11.0% in the first quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock valued at $6,558,000 after purchasing an additional 43,706 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Takeda Pharmaceutical by 43.6% in the first quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock valued at $2,911,000 after buying an additional 59,442 shares during the period. Finally, Focus Partners Wealth lifted its stake in shares of Takeda Pharmaceutical by 4.1% in the first quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock valued at $1,230,000 after buying an additional 3,239 shares during the period. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.